Type 1 diabetes is treated with glucose monitor and insulin injections.

Type 1 diabetes is potentially treatable with immune system inhibition that allows beta pancreas cells to regenerate and make insulin again. Only a subset of the immune system is inhibited and up-regulation of another factor in the immune system aid in the regeneration of beta cells. Redifferentiation of alpha cells in beta cells have also been demonstrated.

Further on, another factor clears memory T-cells from the pancreas resulting in the auto-immune response to be reset.

This work was adapted by other auto-immune diseases but applies to type 1 diabetes.

This is the strategy of Janus kinase (Jax) inhibitors for vitiligo, precise inhibition of interleukin in vitiligo might produce an even better result as they also inhibit the memory T-cells that remain in the area. Target immunotherapy is broad potential for many immune related diseases.

This is a work described by Dr. John Harris, Associate Professor in the Department of Dermatology at the University of Massachusetts Medical School (UMMS) in Worcester, MA. Dr. Harris directs the Vitiligo Clinic and Research Center at UMMS.